Artiva Biotherapeutics

ARTV · NASDAQ

$6.56+$0.67 (+11.38%)TodayMarket closed ·
Prev close $5.89

Who owns ARTV

Largest institutional holders, from their latest 13F filings

The 10 largest institutions hold 80.9% of ARTV’s shares.

  • RA Capital Management, LP37.6%
  • GC Biopharma Corp12.3%
  • Viking Global Investors LP5.4%
  • Blackstone Alternative Asset Management, L.P.4.9%
  • Next 6 largest institutions20.7%
  • All other shareholders19.1%
Top institutional holders of ARTV
HolderShares% of shares
RA Capital Management, LP18.26M37.58%
GC Biopharma Corp6.00M12.35%
Viking Global Investors LP2.60M5.36%
Blackstone Alternative Asset Management, L.P.2.40M4.95%
5AM Ventures2.35M4.84%
VR Adviser, LLC2.04M4.21%
Franklin Advisers, Inc.2.00M4.11%
Caligan Partners, LP1.74M3.57%
Vanguard Capital Management, LLC981.82K2.02%
Samsara BioCapital, LLC954.86K1.97%

Largest mutual fund holders

Top mutual fund holders of ARTV
HolderShares% of shares
Franklin Templeton Investment Funds -Biotechnology Discovery940.34K1.94%
Vanguard Total Stock Market Index Fund699.90K1.44%
Franklin Biotechnology Discovery Fund542.37K1.12%
Franklin Small Cap Growth Fund456.47K0.94%
Vanguard Extended Market Index Fund269.15K0.55%

Insider trades

Form 4 filings by officers, directors and large holders

Over the last 6 months, insiders bought $133.89M (21 trades) and sold $2.48M (17 trades) of ARTV on the open market.

Latest ARTV insider transactions
InsiderTypeSharesValue
Aslan FredSale23.46K$168.88K
Banerjee SubhashisSale1.10K$7.51K
Aslan FredSale61.70K$421.83K
Horan ChristopherSale10.34K$70.70K
Bush JenniferSale8.37K$57.23K
Aslan FredAward315.00K—
Aslan FredAward110.00K—
Aslan FredAward155.00K—
Aslan FredAward45.00K—
Stoppel LauraAward16.25K—

Short interest

Settled Sep 30, 2026

Shares short
2.30M
Days to cover
3.67
% of shares outstanding
4.73%
Average daily volume
625.94K
Change since last report
+11.2%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.